Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Brigham and Women's Hospital
Study ID
NCT06779929
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
40 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This cohort study was initiated to emulate the design of the SURPASS-CVOT trial using observational analogues of the trial design components in a study based on insurance claims data.

Key Dates

Start date
Nov 1, 2024
Status verified
Dec 2025
Primary completion
Dec 1, 2025
Completion
Mar 1, 2026

Study Design

Enrollment
70,000 participants (actual)

Arms

  • Arm: Tirzepatide
    Patients who initiated tirzepatide with no use in the prior 180 days
  • Arm: Dulaglutide
    Patients who initiate dulaglutide with no use in the prior 180 days
  • Arm: Semaglutide
    Patients who initiate semaglutide with no use in the prior 180 days

Primary Outcome Measure

Composite CV outcome [ Time Frame: From treatment initiation to end of follow up, up to 48 months. ]

Locations (1)

FacilityCityStateZIPSite coordinators
Brigham and Women's HospitalBostonMassachusetts02120-

Find similar trials in Boston, MA

By condition
Type 2 diabetes
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
Brigham and Women's Hospital· Boston, MA

Related Studies